Small Molecules and Pancreatic Cancer Trials and Troubles
Authors:
- Sneha GovardhanagiriSGSneha Govardhanagiri
- Shipra BethiSBShipra Bethi
- Ganji Purnachandra NagarajuGNGanji Purnachandra Nagaraju
- 1 January 2019
- book chapter
- Published by Elsevier
- p. 117-131
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does NotClinical Cancer Research, 2012
- MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancerProceedings of the National Academy of Sciences, 2012
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancerGut, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detectionBest Practice & Research Clinical Gastroenterology, 2010
- Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology & Hepatology, 2009
- Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic CancerClinical Cancer Research, 2009
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002